Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/28249

Title:	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
Authors:	Pozniak, Anton Arribas, Jose R Gathe, Joseph Gupta, Samir K Post, Frank A Bloch, Mark Avihingsanon, Anchalee Crofoot, Gordon Benson, Paul Lichtenstein, Kenneth Ramgopal, Moti Chetchotisakd, Ploenchan Custodio, Joseph M Abram, Michael E Wei, Xuelian Cheng, Andrew McCallister, Scott SenGupta, Devi Fordyce, Marshall W View more
Mesh:	Adult Albuminuria Bone Density Cobicistat Drug Therapy, Combination Emtricitabine Female Glomerular Filtration Rate HIV Infections Humans Male Middle Aged Proteinuria Quinolones Renal Insufficiency Tenofovir Drug Substitution View more
Issue Date:	15-Apr-2016
Citation:	J. Acquir. Immune Defic. Syndr..2016 Apr;(71)5:530-7
Abstract:	Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F), and TAF 10 mg (E/C/F/TAF) in HIV-1-infected patients with mild to moderate renal impairment.
PMID:	26627107
URI:	https://hdl.handle.net/20.500.12530/28249
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Hospitales > H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC4804743.pdf		477.09 kB	Adobe PDF	View/Open